natgillin/translations-raw huggingface dataset:
The method of embodiment 20, wherein the contacting occurs in a reaction mixture which comprises a tRNA synthetase capable of aminoacylating the orthogonal tRNA with the compound of any of embodiments 1-14. 
Metoda iz patentnog zahtjeva 14, gdje se stupanje u vezu javlja u reakcijskoj smjesi koja sadrži tRNK sintetazu koja aminoacilira ortogonalnu tRNK sa spojem iz patentnog zahtjeva 1 ili 2.
The antibody or functional fragment according to any one of claims 1-9 for treating a disorder or condition associated with the undesired presence of CD38+ cells, wherein said disorder or condition is a haematological disease, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia. 
Uporaba prema patentnom zahtjevu 16 ili humano antitijelo ili njegov funkcionalni fragment za uporabu prema patentnom zahtjevu 17, pri čemu je hematološka bolest multipli mijelom, kronična limfocitna leukemija, kronična mijelogena leukemija, akutna mijelogena leukemija ili akutna limfocitna leukemija.
A packaging according to claim 5, wherein the two hinges each define a groove on a backside of the packaging, each groove being adapted to engage with corresponding protrusions on the first and second outer parts for attaching these to the inner part. 
Pakiranje u skladu s patentnim zahtjevom 12, naznačeno time, što dva panta imaju utor na stražnjoj strani pakiranja, pri čemu su navedeni utori prilagođeni da zahvate odgovarajuća izbočenja na prvom i drugom vanjskom dijelu i/ili na metalnom sloju/dijelu radi pričvršćenja ovih na unutarnji dio.
The starting compounds in Scheme A are known compounds which are commercially available. 
Polazni spojevi u shemi A su poznati spojevi koji su komercijalno dostupni.
The automatic analyzer according to claim 1, wherein the absorbance determining section determines absorbance when the plurality of standard deviations decrease over time and the number of standard deviations smaller than the threshold is 2 or more. 
Postupak prema zahtjevu 9, naznačen time da (iv) određuje apsorbanciju kada se mnoštvo standardnih devijacija smanjuje tijekom vremena i broj standardnih devijacija koji ne prelazi prag (LT) je 2 ili više.
Ra is a hydrogen, cyano, methyl, trifluoromethyl, ethyl, phenyl, methoxy, difluoromethoxy, trifluoromethoxy or ethoxy group, or two Ra radicals that are bonded to adjacent carbon atoms, may also be an —O—CH2—O— or —O—CH2—CH2—O— group, 
R, je vodik, fluor, klor ili atom broma ili skupina cijano, metil, trifluorometil, etil, fenil, metoksi, difluorometoksi, trifluorometoksi ili etoksi, ili dvije skupine R,, kada su one vezane na susjedne atome ugljika, mogu također biti -O-CH2-O-skupina ili skupina,
The umbrella as recited in claim 1, wherein the umbrella has a telescoping handle and before an inflation, the inflatable envelope is contained inside the telescoping handle. 
Kišobran kao što je navedeno u patentnom zahtjevu 1, naznačen time da kišobran ima teleskopsku dršku (800) i prije napuhivanja, omotač za napuhavanje se nalazi unutar teleskopske drške; i učinak napuhavanja se može dobiti pumpanjem teleskopske drške.
An antibody or a functional protein comprising an antigen binding portion thereof according to claim 3, comprising a heavy chain variable region CDR1 of SEQ ID NO: 9; a heavy chain variable region CDR2 of SEQ ID NO: 23; a heavy chain variable region CDR3 of SEQ ID NO: 37; a light chain variable region CDR1 of SEQ ID NO: 51; a light chain variable region CDR2 of SEQ ID NO: 65; and a light chain variable region CDR3 of SEQ ID NO: 79. 
Protutijelo ili funkcionalni protein koji obuhvaća njegov dio koji veže antigen, prema zahtjevu 3, naznačen/o time, da obuhvaća CDRI varijabilnog područja jakog lanca od SEQ ID NO: 9; CDR2 varijabilnog područja jakog lanca od SEQ ID NO: 23; CDR3 varijabilnog područja jakog lanca od SEQ ID NO: 37; CDRI varijabilnog područja slabog lanca od SEQ ID NO: 51; CDR2 varijabilnog područja slabog lanca od SEQ ID NO: 65; i CDR3 varijabilnog područja slabog lanca od SEQ ID NO: 79.
the wt human extracellular domain of FAPa having seq ID:448 on the cell surface; 
(i) ljudsku izvanstaničnu domenu FAPa divljeg tipa sa SEQ ID:448 na površini stanice;
wherein the composition comprises at least about 80 % (by wt) of polyethylene oxide and at least about 50 % (by wt) of polyethylene oxide having, based on rheological measurements, a molecular weight of at least 1,000,000. 
najmanje oko 20% (težinski) ili najmanje oko 30 % (težinski) ili najmanje oko 50 % (težinski) polietilen oksida koji ima, prema reološkim mjerenjima, molekularnu težinu od najmanje 1,000,000.
In certain embodiments, for example, the alkaline earth metal is calcium or magnesium. 
(V) _R,iR, uzeti zajedno su zemnoalkalijski metal, pri čemu je zemnoalkalijski metal poželjno kalcij ili magnezij.
The dosage form of claim 6, wherein the pharmaceutically acceptable non-ionic solubilizer is selected from the group consisting of sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters and alpha tocopheryl polyethylene glycol succinate; and the pharmaceutically acceptable anionic solubilizer is sodium laurylsulfate. 
Oblik doziranja u skladu s patentnim zahtjevom 6, naznačen time, da se farmaceutski prihvatljiv neionski solubilizator odabire iz skupine koju čine esteri masnih kiselina sorbitana, esteri masnih kiselina polioksietilen sorbitana i alfa tokoferil polietilen glikol sukcinat; a farmaceutski prihvatljiv anionski solubilizator natrij lauril sulfat.
A system according to any preceding claim wherein the access interface includes a server to receive a user request to observe the simulated event and to transmit a data stream to the user, the data stream representing the simulated event and being suitable to be used to simulate the event on a user display. 
Sustav prema bilo kojem od zahtjeva 3 do 7, naznačen time što sučelje za pristup (8) obuhvaća poslužitelja (server) koji zaprima zahtjev korisnika za promatranje simuliranog događaja i prenosi tok podataka korisniku, tok podataka predstavlja simulirani događaj i pogodan je za uporabu za simulaciju događaja na ekranu korisnika.
The composition according to claim 1, wherein the drug-containing layer further comprises a tackifier selected from the group consisting of hydrocarbon resins, rosin resins and terpene resins. 
Komplet prema bilo kojem prethodnom zahtjevu, naznačen time da sloj koji sadrži lijek dodatno sadrži ljepljivo sredstvo odabrano iz skupine koja sadrži smole ugljikovodika, smole kalofonija i terpenske smole.
A kit comprising the double-stranded short interfering nucleic acid (siNA) molecule according to claim 1. 
Komplet, naznačen time, da sadržava molekulu s dvolančanom kratkom interferirajućom nukleinskom kiselinom (SINA) u skladu s patentnim zahtjevom 1.
R8, R9, R10 and R11 independently from each other stand for H, or C1-C6 alkyl; or any two of R8, R9, R10 and R11 together with the carbon atom to which they are bound may form a 3-6 membered saturated carbocyclic ring; R and R′ are hydrogen; 
R8, R9, R10 1 R11 međusobno neovisno predstavljaju H, ili C;-Cg alkil; ili bilo koja dva od R8, R9, RIO i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten; R iR' su vodik;
Cancer Ther., 1(12), 1089–1095 (2002) disclose the compound of the formula 
Cancer Tber., 1 (12), 1089-1095 (2002) razotkriva spoj formule
The apparatus according to claim 1, further comprising: an ammonia collection system for collecting ammonia generated from the treatment of the organic mass; and 
Uređaj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da nadalje obuhvaća sustav za recikliranje amonijaka koji se stvara putem obrađivanja organske mase, pri čemu taj sustav uključuje:
The method according to Claim 4, wherein the pulp in the furnish comprises at least 60% by weight pre-dried fiber or, wherein the pulp in the furnish comprises at least 75% by weight pre-dried fiber. 
Metoda u skladu s patentnim zahtjevom 4, pri čemu pulpa u sirovini sadrži najmanje 60% od mase prethodno osušenih vlakana ili, pri čemu pulpa u sirovini sadrži najmanje 75% od mase prethodno osušenih vlakana.
The method of the preceding claim, wherein said secret further depends from said ID code. 
Metoda u skladu s patentnim zahtjevom 7, naznačena time, da se tajnost nadalje izvodi iz ID koda.
The radio communication base station (100) of any of preceding claims, wherein a part or all of the receiver (101), measurer (102,) and transmitter (105) are integrated into a single chip. 
Radio komunikacijski terminalni uređaj (300) sukladno bilo kojem od prethodnih zahtjeva, naznačen time da su dio 1li cijeli prijemnik (301), kontroler (302) 1 odašiljač (303) integrirani u jedan čip.
is hydrogen, C1 to C6 alkyl, phenyl unsubstituted or substituted by C1 to C6 alkyl, COR6 acyl group (R6 being hydrogen; C1 to C6 straight chain or branched alkyl; phenyl or benzoyl respectively unsubstituted or substituted by C1 to C6 alkyl), or any group leading to hydroxyl upon biological metabolization or chemical deprotection; and salts thereof; 
je vodik, C1 do C6 alkil, fenil nesupstituiran ili supstituiran s C1 do C6 alkilom, COR6 acilnom skupinom (R6 je vodik; C1 do C6 ravnolančani ili razgranati alkil; odnosno fenil ili benzoil nesupstituiran ili supstituiran s C1 do C6 alkilom), ili bilo kojom skupinom koja vodi do hidroksila nakon biološke razgradnje ili kemijskog uklanjanja zaštite; i njegove soli;
A tablet may contain certain excipients in addition to the active principle asenapine maleate in the crystalline orthorhombic form such as diluents, binders, glidants and lubricants, which serve to impart satisfactory processing and compression characteristics to the tablet, as well as disintegrants and flavoring agents, which gives additional desirable physical characteristics to the finished tablet. 
Tableta može dodatno uz aktivni osnovni sastojak asenapin maleat u kristalnom ortorombskom obliku sadržavati određene ekscipijente kao što su razrjeđivala, vezivne tvari, tvari koje pospješuju klizanje i lubrikanti, čija je uloga da omoguće zadovoljavajuću obradu i kompresiju karakterističnu za tabletu, kao i tvari za raspadanje i aromu, koji daju dodatna poželjna fizička svojstva gotovoj tableti.
The monoclonal antibody or antigen-binding portion thereof of claim 5, wherein the antibody or antigen-binding portion thereof is an antibody or antigen-binding portion thereof according to claim 1 i), and wherein the binding to a conformational or discontinuous epitope on human GDF-15 is binding to a conformational or discontinuous epitope comprised by the amino acid sequences of SEQ ID No: 25 and SEQ ID No: 26. 
Monoklonsko antitijelo ili njegov dio koji se veže na antigen sukladno zahtjevu 5, naznačeno time, da antitijelo ili njegov dio koji se veže na antigen je antitijelo ili njegov dio koji se veže na antigen sukladno zahtjevu 1 i), naznačen time, da vezanje na konformacijski ili diskontinuirani epitop na humanom GDF-15 se veže na konformacijski ili diskontinuirani epitop koji sadrži aminokiselinske sekvence SEQ ID NO: 25 i SEQ ID NO: 26.
R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkynyl, cyano, haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, nitro, NRARB, and (NRARB)carbonyl; 
Ri, R2, i Rs su neovisno odabrani iz skupine koja se sastoji od vodika, alkenila, alkoksi, alkoksikarbonila, alkila, alkinila, cijano, haloalkoksi, haloalkila, halogena, hidroksi, hidroksialkila, nitro, NR,R; i (NRaRe)karbonila;
A method of making a combination vaccine comprising inactivated poliovirus type 1 for immunising a human host, comprising the steps of: mixing diphtheria toxoid and tetanus toxoid, followed by the addition of inactivated poliovirus type 1 at a dose greater than 10 D-antigen units and less than 20 D-antigen units. 
tetanusni toksoid; umrtvljene cijele stanice bakterije Bordetella pertussis; ili dvije ili više acelularnih komponenti bakterije hripavca (Pa) (primjerice pertusisni toksoid, filamentozni hemaglutinin (FHA) i pertaktin (PRN)), te; inaktivirani poliovirus tip 1, u dozi većoj od 10 D-antigenskih jedinica, a manjoj od 20 D-antigenskih jedinica, gdje navedeno cjepivo uglavnom ne sadrži tiomersal.
A host cell comprising the nucleic acid according to claim 13 and/or the vector according to claim 14. 
Stanica domaćin, naznačena time što sadrži vektor u skladu s patentnim zahtjevom 12 i/ili nukleinsku kiselinu u skladu s patentnim zahtjevom 11.
Pharmaceutical composition comprising: 
Farmaceutski sastav, naznačen time, da obuhvaća:
The lipid of claim 1, wherein at least one of the R1, R2, and R3 alkyl chains comprises a cycloalkyl moiety and/or a double bond. 
Lipid skladu s patentnim zahtjevom 1, naznačen time, da najmanje jedan od R!, R* i R* ima dvostruku vezu, poželjno cis dvostruku vezu.
The antibody or antigen-binding fragment for its use according to claim 12, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 14, and a light chain comprising the amino acid sequence of SEQ ID NO: 15. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 19, naznačen time što je barem jedno terapeutsko sredstvo je odabrano iz skupine koju čine bisfosfonat, paratiroidni hormonski analog, kalcitonin, i selektivni modulator receptora estrogena (SERM).
The nanoparticles for use according to any one of claims 1-8, wherein the cancer is a solid tumor or a hematopoietic tumor, preferably selected from the group consisting of hepatocellular carcinoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic myelogenous leukemia, Hodgkin's disease, diffuse large B-cell lymphoma, small cell lung cancer, colorectal cancer, pancreas cancer, breast cancer, ovary cancer, uterine cancer, cervix cancer, head and neck cancer, brain cancer, blade cancer, multiple myeloma, neuroblastoma, Edwing's sarcoma, osteosarcoma, soft tissue sarcoma, thyroid cancer, prostate cancer, stomach cancer, nephroblastoma, Kaposi's sarcoma, and non-Hodgkins lymphoma. 
Nanočestice za uporabu prema bilo kojem od zahtjeva 1-8, naznačene time da karcinom je solidni tumor ili hematopoetski tumor, poželjno odabran iz skupine koja sadrži hepatocelularni karcinom, akutnu limfoblastičnu leukemiju, akutnu mijeloičnu leukemiju, kroničnu mijelogenu leukemiju, Hodgkinsovu bolest, difuzni B- velikostanični limfom, rak pluća malih stanica, rak debelog crijeva, rak gušterače, rak dojke, rak jajnika, rak maternice, rak grlića maternice, rak glave i vrata, rak mozga, rak mjehura, multipli mijelom, neuroblastom, Ewingov sarkom, osteosarkom, sarkom mekog tkiva, rak štitnjače, rak prostate, rak želuca, nefroblastom, Kapozijev sarkom, te ne-Hodgkinov limfom.
all other amino acid residues are L-amino acid residues, if not explicitly designated as D-amino acid residues, following standard IUPAC nomenclature, and tigecycline, or pharmaceutically acceptable salts, or hydrates or solvates thereof. 
Orn je ($)-2,5-diaminopentanska kiselina; i tigeciklin, ili njegove farmaceutski prihvatljive soli, ili hidrati ili solvati.
A compound or a pharmaceutically acceptable salt thereof, or composition of any of claims 1-18 for use in the treatment of pain. 
19. Tvar ili njena farmaceutski prihvatljiva sol, ili sastav iz bilo kojeg od patentnih zahtjeva 1-18 za uporabu u 5
Method according to claim 12, characterised in that the randomly modified nucleic acid molecule comprises at least one nucleotide repeating unit having the sequence 5'-NNS-3', 5'-NNN-3' or 5' - NNK-3' . 
. Postupak u skladu s zahtjevom 25, naznačen time, da navedena modificirana nukleotidna sekvenca obuhvaća barem jedanu ponavljajuću jedinicu nukleotida koja ima sekvencu 5'-NNS-3', 5'-MNN-3' ili 5'-NNK-3',
approximately 0.1 N NaOH solution, if adjustment to a pH of approximately 4.5 is required, and 
(g) oko 0.1 N otopine NaOH, ako je potrebno za postavljanje pH od oko 4.5, 1
Advantageously, said containers are chosen from the group made up of cans, cardboard boxes of the single-serving carton or Tetrapack® type, glass or plastic bottles. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što su navedeni spremnici (2) odabrani iz skupine koja se sastoji od limenki, kartonskih kutija tetraedarskog tipa ili tetrapaka&, staklenih ili plastičnih boca.
A container comprising the composition of claim 1 . 
Spremnik koji sadrži sastav prema bilo kojem od prethodnih zahtjeva.
For single dose inhalers of the first type, single doses have been weighed by the manufacturer into small containers, which are mostly hard gelatine capsules. 
Kod inhalatora za pojedinačnu dozu iz prve skupine, pojedinačne doze se tijekom proizvodnje odmjere u male spremnike koji su obično kapsula od tvrde želatine.
A pressurized metered dose inhaler comprising a canister filled with the pharmaceutical aerosol formulation of any one of the claims I to 4, and a metering valve for delivering therapeutically effective doses of the active ingredients. 
Inhalator sa stlačenim inhalatom, naznačen time da sadrži spremnik napunjen farmaceutskom aerosolnom formulacijom iz bilo kojeg od patentnih zahtjeva 1 do 4, te odmjerni ventil za isporuku terapijski učinkovitih doza aktivnih tvari.
The peptide for use according to Claim 3, wherein said fusion protein comprises the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid za upotrebu u skladu s patentnim zahtjevom 1, pri čemu se navedeni fuzijski protein sastoji od N-terminalnih aminokiselina HLA-DR invarijantnog lanca vezanog za antigene (Ii).
After this time, the solution was cooled to RT and the solid was collected by filtration to give the title compound, 4,5-dichloro-1,2-dihydropyridazine-3,6-dione (65gm, 90% yield) as white solid. 
Nakon ovog vremena, otopina je ohlađena na sobnu temperaturu i krutina je sakupljena filtracijom pri čemu se dobiva spoj iz naslova, 4,5-dikloro-1,2-dihidropiridazin-3,6-dion (65 mg, 90% prinos) kao bijela krutina.
A dose counter according to claim 3, wherein the second ratchet drive pawl is resiliently biased into contact with the gear teeth of the gear wheel with which it is arranged for engagement, the pawl being displaceable away from the gear wheel against the bias. 
Brojač doza u skladu s patentnim zahtjevima 2 ili 3, pri čemu je drugi pogon zapornog zaklopca (132) elastično odmaknut u kontaktu sa zupcima zupčanika kotača sa zupčanikom s kojim je postavljen za pokretanje, zaklopac se može odmaknuti od kotača sa zupčanikom naspram odstupanju.
Salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine selected from the DL-lactic acid addition salt, the glutaric acid addition salt, the L-aspartic acid addition salt and the glutamic acid addition salt. 
Tekući farmaceutski oblik koji sadrži sol 4-[2-(4-metilfenilsulfanil)fenil]piperidina izabranu između adicijske soli DL-mliječne kiseline, adicijske soli glutarne kiseline, adicijske kiseline L-asparaginske kiseline i adicijske soli glutaminske kiseline.
Consequently, in a preferred embodiment, after the sensitization with the anti L1 antibody of the invention, the patient is further treated with said chemotherapeutic drug or with said radiotherapy. 
Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s patentnim zahtjevom 5 ili 6, naznačena time što se nakon sensibiliziranja vežućom molekulom pacijent dodatno liječi. navedenim kemoterapijskim lijekom ili radioterapijom.
The process according to claim 15, wherein the isolated polypeptide with esterase activity is the amino acid sequence shown in SEQ ID NO: 2. 
Postupak prema zahtjevu 16 naznačen time da izolirani polipeptid s aktivnošću esteraze je sekvenca amino kiseline prikazana u SEQ ID No. 2.
The composition according to claim 3, wherein said antiviral agent is selected from: ribavinn and amantadine. 
Sastav prema zahtjevu 13, naznačen time, da je spomenuto antivirusno sredstvo odabrano od ribavirina i amantadina.
Thus the compound of Example 1 has been administered to rats at doses of 30mg/kg for 7 days and no adverse toxicological effects were observed. 
Tako je spoj iz Primjera 1 7 dana primijenjivan na štakorima u dozama od 30 mg/kg, bez opaženih štetnih toksikoloških učinaka.
The antitumor preparation according to claim 6 in a pharmaceutical form comprising a compound pharmaceutical agent comprising 3 ingredients, i.e., tegafur, gimeracil, and oteracil potassium, as active ingredients, and a pharmaceutical agent comprising cis-oxalate(1R,2R -diaminocyclohexane)platinum(II) as an active ingredient. 
Farmaceutski sastav prema zahtjevu 7, naznačen time, da obuhvaća farmaceutsko sredstvo koje sadrži tegafur, gimeracil i kalij oteracil, i farmaceutsko sredstvo koje sadrži cis-oksalat(1R,2R-diaminocikloheksan)platina(II).
The method of claim 24, wherein the subject has a cancer selected from the group consisting of: non-small cell lung cancer (NSCLC), endometrial cancer, and ovarian cancer. A method for increasing the efficacy of cancer therapy comprising: 
Protutijelo protiv FOLRI ili imunokonjugat protiv FOLRI, namijenjeni upotrebi u skladu s patentnim zahtjevom 1, naznačeni time što subjekt ima a rak koji se bira iz skupine koju čine: rak jajnika, rak endometrija, rak potrbušnice ili rak pluća.
Panel according to any of the claims 12 to 15 having a modulus of elasticity ranging from 2500 N/mm2 to 3500 N/mm2, said modulus of elasticity being measured in a panel having a thickness of 20 millimetres. 
Ploča u skladu s bilo kojim od patentnih zahtjeva 12 do 15, naznačena time, da je njezin modulus elastičnosti u rasponu od 2 500 N/mm" do 3 500 N/mm', pri čemu se navedeni mođulus elastičnosti mjeri u ploči debljine 20 milimetara.
is an antibody or antibody fragment coupled to an effector molecule which mediates a therapeutic effect selected from the group consisting of an immune effector molecule, a toxin and a radioisotope. 
protutijelo ili fragment protutijela konjugiran s efektorskom molekulom koja provodi terapijski učinak, poput imunosne efektorske molekule, toksina ili radioizotopa.
is substituted 4-12 membered aromatic heterocyclic radical, the number of heteroatoms on the substituted aromatic heterocyclic radical is 1 to 4, the heteroatom is N, O or S; the substituent on the substituted heteroaromatic ring is -H, C1 - C6 alkyl, substituted aryl, -CF3, 5-10 membered aromatic heterocyclic radical, carboxyl or C3 - C6 cycloalkyl; and the substituent on the substituted aryl is -H or halogen; 
je supstituirani 4-12-člani aromatski heterociklični radikal, ili broj heteroatoma na supstituiranom aromatskom heterocikličnom radikalu je 1 do 4, heteroatom je N, O ili S; supstituent na supstituiranom heteroaromatskom prstenu je –H, C1 – C6 alkil, supstituirani aril, -CF3, 5-10-člani aromatski heterociklični radikal, karboksil ili C3 – C6 cikloalkil; te je supstituent na supstituiranom arilu –H ili halogen;
The therapeutic agent or prophylactic agent according to claim 36, wherein the acid-related disease or symptom is gastric ulcer, duodenal ulcer, anastomotic ulcer, gastroesophageal reflux disease, Zollinger-Ellison syndrome, symptomatic gastroesophageal reflux disease, endoscopically negative gastroesophageal reflux disease, non-erosive gastroesophageal reflux disease, or acute gastric mucosal lesion. 
Terapijsko sredstvo ili profilaktičko sredstvo u skladu s patentnim zahtjevom 36, naznačeno time, da bolesti povezane s kiselinom ili simptomom jesu čir želuca, duodenalni ulcer, anastomoza ulcera, bolest gastroezofagealnog refluksa, Zollinger-Ellisonov sindrom, simptomatična bolest gastroezofagealnog refluksa, endoskopski negativna bolest gastroezofagealnog refluksa, ne-erozivna bolest gastroezofagealnog refluksa ili akutna lezija želučane sluznice.
A method of coating a substrate according to any of claims 1, 3-9 or 11, wherein the topcoat system comprises a silyl acrylate based self polishing topcoat or an epoxy based topcoat. 
Metoda premazivanja supstrata sukladno bilo kojem od zahtjeva pod 1, 3do 9 ili 11, naznačena time što se sustav završnog premaza sastoji od samopolirajućeg završnog premaza na bazi silil akrilata ili završnog premaza na bazi epoksida. t>&